Kymera Therapeutics Inc. Common Stock (KYMR)

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, an…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

273

Website

www.kymeratx.com/

Fundamentals

1-day range

$117.63$121.98

Market cap

$8.25B

P/E (trailing)

—

P/E (forward)

-24.06

EPS (trailing)

$-3.24

Dividend yield

—

Beta

1.97

Avg. volume

858.6K

Forecasts

22 analyst ratings

Kymera Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.25BP/E —
  $39.84$130.05
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.72BP/E 22.14
  $32.53$57.82
• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $9.76BP/E 27.63
  $61.23$109.66
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.78BP/E —
  $44.12$78.48
• ADPT

  Adaptive Biotechnologies Corporation Common Stock

  $25.19

  ▼ 4.73%
  Market cap $3.70BP/E —
  $12$26.87
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.60BP/E —
  $3.5$21.27
• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.67BP/E —
  $16.02$38.26

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151
  benzinga · 8/27/2026
• Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
  Benzinga · 8/6/2026
• Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/5/2026
• Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/5/2026
• Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate
  Benzinga · 8/5/2026

• Terence Rooney · July 27, 2026 · Grant

  76.0K
• Terence Rooney · July 27, 2026 · Grant

  38.0K
• Nello Mainolfi · July 7, 2026 · Option Exercise

  4.4K
• Nello Mainolfi · July 7, 2026 · Option Exercise

  45.6K
• Nello Mainolfi · July 7, 2026 · Sale

  50.0K @ $119
• Nello Mainolfi · July 7, 2026 · Option Exercise

  50.0K @ $2.08
• Noah Goodman · July 1, 2026 · Sale

  3.4K @ $114.29
• Nello Mainolfi · July 1, 2026 · Option Exercise

  80.0K @ $2.08
• Nello Mainolfi · July 1, 2026 · Sale

  3.3K @ $116.56
• Nello Mainolfi · July 1, 2026 · Sale

  44.0K @ $115.69
• Nello Mainolfi · July 1, 2026 · Sale

  24.1K @ $114.96
• Nello Mainolfi · July 1, 2026 · Sale

  6.6K @ $113.98
• Nello Mainolfi · July 1, 2026 · Sale

  1.9K @ $112.8
• Bruce N. Jacobs · June 30, 2026 · Option Exercise

  61.4K @ $5.33
• Bruce N. Jacobs · June 30, 2026 · Sale

  3.2K @ $117.7

Institutional Ownership

March 31, 2026

Total shares held

92.98M

Total value held

$6.77B

Institutional holders

251